■人工耳蜗的疗效随访主要集中在术后3年,观察超过5年的研究很少见,特别是中国本土品牌。
■Nurotron(中国国产人工耳蜗品牌)在2009年参加临床试验的CI接受者进行了为期10年的前瞻性随访,提供数据指导医生和患者。
从2009年12月到2010年4月,57名受试者在多个中心接受了NurotronVenusCI手术,并在开机后1,2,3,4,5和10年继续随访和评估.
■所有受者均成功植入CI,随后使用无困难,据报道1例植入后9年再次植入。辅助听阈在接通后1个月显著提高(p<0.0001),之后保持稳定10年。语音识别得分明显高于术前结果(p<0.05),并在打开后3年持续改善。手术后10年,大多数受试者在大多数子项目中的QOL得分均有所提高.
■NurotronVenusCI系统提供长期,听力语音辅助能力的稳定结果,可以改善CI接受者的生活质量。
UNASSIGNED: Follow-up of cochlear implant effectiveness is mainly focused on 3 years postoperatively, and studies with more than 5 years of observation are rare, especially for local Chinese brands.
UNASSIGNED: Nurotron (Chinese domestic cochlear implant brand) CI recipients who participated in the clinical trial in 2009 were followed-up for 10 years prospectively, providing data to guide doctors and patients.
UNASSIGNED: From December 2009 to April 2010, 57 subjects underwent Nurotron Venus CI surgery at multiple-centers, and were continued to be followed up and assessed at 1, 2, 3, 4, 5, and 10 years after switch on.
UNASSIGNED: All recipients were successfully implanted with CIs with no difficulty in subsequent use with one reported case of re-implantation at 9 years after implantation. The aided hearing thresholds were significantly improved at one month after switch on (p < 0.0001) and remained stable afterwards for 10 years. Speech recognition scores were significantly higher than pre-operative results (p < 0.05) and continued to improve till 3 years after switch on. At 10 years post-operation, most subjects had improved QOL scores in most sub-items.
UNASSIGNED: Nurotron Venus CI System provides long-term, stable results in hearing speech assistance capabilities and can improve the quality of life of CI recipients.